10x Genomics Inc. (TXG): A Technical View

As of Friday close, 10x Genomics Inc.’s (NASDAQ:TXG) stock was up $6.71, moving up 16.40 percent to $47.63. The average number of shares traded per day over the past five days has been 2,690,220 shares. 2 times new highs have been achieved over the past 5 days, with a -$3.56 fall in that time frame. In the last twenty days, the average volume was 1,928,960, while in the previous 50 days, it was 1,379,392.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Since last month, TXG stock retreated -30.37%. Shares of the company fell to $36.76 on 05/12/22, the lowest level in the past month. A 52-week high of $208.99 was reached on 01/03/22 after having rallying from a 52-week low of $36.76. Since the beginning of this year, TXG’s stock price has dropped by -68.02% or -$101.33, and marked a new high 1 time. However, the stock has declined by -77.21% since its 52-week high.

10x Genomics Inc. (TXG) last reported insider trading activity 81 days ago on Feb 22. Saxonov Serge, the Chief Executive Officer of the company, disposed of 551 shares for $78.60 on Feb 22. It resulted in a $43,309 divestment by the insider. Hindson Benjamin J. sold 360 shares at an average price of $78.59 on Feb 22. The insider now owns 160,326 shares following the transaction. On Feb 22, Chief Financial Officer McAnear Justin J. sold 288 shares at $78.60 apiece. The transaction was valued at $22,637.

Financial Health

In the three months ended September 29, 10x Genomics Inc.’s quick ratio stood at 6.70, while its current ratio was 7.40, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 83.50% percent. In the year ended September 29, operating margins totaled -16.80%. Based on annual data, TXG earned $416.4 million in gross profit and brought in $490.49 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -6.90%. Return on equity (ROE) for the past 12 months was -11.10%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. TXG’s revenue rose 1.99% to $125.3 million during the quarter, while net income inched up to $114.5 million. While analysts expected 10x Genomics Inc. to report -$0.2 quarterly earnings, the actual figure was -$0.15 per share, beating the consensus estimate by 25.00%. During the quarter, the company generated -$8.51 million in EBITDA. The liabilities of 10x Genomics Inc. were 201.26 million at the end of its most recent quarter ended September 29, and its total debt was $80.2 million. The value of shareholders’ equity is $112.84 million.

Technical Picture

This quick technical analysis looks at 10x Genomics Inc.’s (TXG) price momentum. With a historical volatility rate of 121.25%, the RSI 9-day stood at 43.72% on 13 May.

With respect to its five-day moving average, the current 10x Genomics Inc. price is down by -6.95% percent or -$3.56. At present, TXG shares trade -26.59% below its 20-day simple moving average and -65.68% percent below its 100-day simple moving average. However, the stock is currently trading approximately -35.67% below its SMA50 and -74.13% below its SMA200.

Stochastic coefficient K was 27.34% and Stochastic coefficient D was 15.75%, while ATR was 5.65. Given the Stochastic reading of 59.76% for the 14-day period, the RSI (14) reading has been calculated as 40.02%. As of today, the MACD Oscillator reading stands at -4.57, while the 14-day reading stands at -5.66.

Analyst Ratings

10x Genomics Inc. (TXG) has been rated Overweight by analysts. According to 0 brokerage firms , TXG is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate 10x Genomics Inc. stock as buy, with 6 recommending it as overweight.

With a median target price of $100.00, the current consensus forecast for the stock is $80.00 – $115.00. Based on these forecasts, analysts predict 10x Genomics Inc. (TXG) will achieve an average price target of $95.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles